Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).

Ozguroglu, Mustafa; Beuzeboc, Philippe; Massard, Christophe; Rouge, Thibault De La Motte; Delanoy, Nicolas; Elaidi, Reza-Thierry; Oudard, Stephane; Angelergues, Antoine; Maillet, Denis; Flechon, Aude; Mercier, Florence; Guillot, Aline; Le Moulec, Sylvestre; Gravis, Gwenaelle

dc.contributor.author	Ozguroglu, Mustafa
dc.contributor.author	Beuzeboc, Philippe
dc.contributor.author	Massard, Christophe
dc.contributor.author	Rouge, Thibault De La Motte
dc.contributor.author	Delanoy, Nicolas
dc.contributor.author	Elaidi, Reza-Thierry
dc.contributor.author	Oudard, Stephane
dc.contributor.author	Angelergues, Antoine
dc.contributor.author	Maillet, Denis
dc.contributor.author	Flechon, Aude
dc.contributor.author	Mercier, Florence
dc.contributor.author	Guillot, Aline
dc.contributor.author	Le Moulec, Sylvestre
dc.contributor.author	Gravis, Gwenaelle
dc.date.accessioned	2021-03-06T12:21:52Z
dc.date.available	2021-03-06T12:21:52Z
dc.identifier.citation	Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., Le Moulec S., Gravis G., Beuzeboc P., Massard C., et al., "Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).", Genitourinary Cancers Symposium, San-Francisco, Kostarika, 30 Ocak - 01 Şubat 2014, cilt.32
dc.identifier.other	av_f375db24-f90e-4d4d-ade3-3ccccaf78fc9
dc.identifier.other	vv_1032021
dc.identifier.uri	http://hdl.handle.net/20.500.12627/159660
dc.identifier.uri	https://doi.org/10.1200/jco.2014.32.4_suppl.282
dc.language.iso	eng
dc.subject	Sağlık Bilimleri
dc.subject	Dahili Tıp Bilimleri
dc.subject	İç Hastalıkları
dc.subject	Onkoloji
dc.subject	Klinik Tıp
dc.subject	Klinik Tıp (MED)
dc.subject	Tıp
dc.subject	ONKOLOJİ
dc.title	Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
dc.type	Bildiri
dc.contributor.department	, ,
dc.identifier.volume	32
dc.contributor.firstauthorID	143688

Files in this item

Files	Size	Format	View
There are no files associated with this item.

This item appears in the following Collection(s)

Bildiri [64839]

Show simple item record